SpinalCyte Announces Issuance of New Chondrocyte Patents in the U.S. and Japan

Veranex Announces Investment From Summit Partners to Form Comprehensive Concept-to-Commercialization Medtech Services Company

As the first phase in building this global entity, Veranex has acquired three complementary solution providers: Ximedica, Quartesian, and Boston Healthcare Associates. By bringing these companies together, Veranex combines the industry’s key pillars of design and engineering, regulatory, clinical, and market access into a single-source solution.

High Acceptance of Advanced Healthcare Equipment Promoting Growth of a-Si X-ray Flat Panel Detectors | Fact.MR’s Medtech Analysis

Big data and analytics will drive patient outcomes in a big way, and the coming years will witness a growing emphasis on healthcare service providers in the business of gathering and processing patient health data.

SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced the issuance of new patents in the U.S. and Japan. The company’s patent portfolio now includes 39 U.S. and international patents issued with 100+ patents pending focused on the clinical use of fibroblasts. The company received IND clearance from the FDA in November to continue clinical trials into its lead fibroblast cell therapy product, CybroCell, in the treatment of degenerative disc disease.

“Our new patents demonstrate the versatility of our technology to repair cartilage not just in the spine, but throughout the body,” said Pete O’Heeron, Chief Executive Officer of SpinalCyte. “As the leader in the field of human dermal fibroblast therapy, we are excited to continue our clinical work to demonstrate the promise of HDFs for a variety of disease paths.”

The U.S. Patent No. 10,206,954 titled “Adipose Cells for Chondrocyte Applications,” and Japanese Patent No. 6456826 titled “Generation of Cartilage Ex Vivo From Fibroblasts” describe methods to differentiate adipose and fibroblast cells into cartilage using a mold to shape the tissue to replace damaged cartilage. Claims also include using a mixture of chondrocyte-like cells, adipose cells and growth factors delivered to a joint to repair damaged cartilage.

Degenerative disc disease (DDD) is a condition in which a patient’s spinal disc breaks down and can begin to collapse. It is estimated that 85% of people over the age of 50 have evidence of disc degeneration and over 1.3 million procedures a year are performed to treat the disease. The most common treatments for patients with DDD are either discectomy or spinal fusion. Discectomy is the partial or full removal of the degenerated disc to decompress and relieve the nervous system but can cause long term spinal pain. In a spinal fusion procedure, the entire disc is removed and the two adjacent vertebrae are fused together. It often increases strain on the adjacent discs and surrounding tissues leading to further degeneration.

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles